Urogen Pharma Sees Unusually High Options Volume (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) was the recipient of some unusual options trading on Wednesday. Investors acquired 20,427 call options on the company. This represents an increase of 2,706% compared to the average volume of 728 call options.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 139,025 shares in the company, valued at $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the transaction, the chief financial officer directly owned 2,280 shares of the company’s stock, valued at approximately $38,418. The trade was a 49.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at $426,000. TCG Crossover Management LLC bought a new stake in Urogen Pharma in the third quarter valued at about $14,311,000. XTX Topco Ltd acquired a new position in Urogen Pharma in the third quarter valued at about $585,000. Voloridge Investment Management LLC bought a new position in Urogen Pharma during the third quarter worth about $13,715,000. Finally, Verition Fund Management LLC acquired a new position in shares of Urogen Pharma during the 3rd quarter worth about $1,776,000. 91.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on URGN shares. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Urogen Pharma Stock Down 4.0%

Shares of URGN opened at $21.72 on Friday. The stock’s fifty day simple moving average is $22.22 and its 200-day simple moving average is $18.33. The firm has a market capitalization of $1.02 billion, a PE ratio of -6.28 and a beta of 1.21. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 170.59%. Analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.